Common Contracts
1 similar Royalty Agreement contracts
ROYALTY PHARMA AND FERRING PHARMACEUTICALS ENTER INTO US $500 MILLION ROYALTY AGREEMENT FOR NEW INTRAVESICAL GENE THERAPY ADSTILADRIN® (NADOFARAGENE FIRADENOVEC-VNCG)Royalty Agreement • August 23rd, 2023
• Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)
